Company news

Phathom Pharmaceuticals, Inc. news in 2025

Phathom Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA in Eosinophilic Esophagitis

November 5, 2025

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

November 3, 2025

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

November 2, 2025

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

October 29, 2025

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

October 24, 2025

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

October 22, 2025

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

October 19, 2025

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

October 5, 2025

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing

August 19, 2025

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 6, 2025

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

July 27, 2025

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

June 22, 2025

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 22, 2025

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

June 15, 2025

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

June 5, 2025

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

April 30, 2025

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

April 27, 2025

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

April 22, 2025

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

April 15, 2025

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

April 2, 2025

Phathom Pharmaceuticals Announces Leadership Succession

March 31, 2025

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

March 30, 2025

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 5, 2025

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

February 23, 2025

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

January 28, 2025

Calls in 2025

Decks in 2025